{"id":57495,"date":"2024-02-27T17:47:19","date_gmt":"2024-02-27T17:47:19","guid":{"rendered":"https:\/\/medsname.com\/hcqs\/"},"modified":"2026-04-30T10:24:26","modified_gmt":"2026-04-30T10:24:26","slug":"hcqs","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/hcqs\/","title":{"rendered":"HCQS"},"content":{"rendered":"

<\/p>\n

\n

R\u0103spuns rapid<\/h3>\n

HCQS<\/strong> con\u021bine sulfat de hidroxiclorochin\u0103<\/strong> 200 mg \u0219i 400 mg (Cipla). Trateaz\u0103 \u0219i previne malarie sensibil\u0103 la clorochin\u0103<\/strong>, \u0219i este aminochinolina de prim\u0103 inten\u021bie pentru artrita reumatoid\u0103<\/strong>, lupus eritematos sistemic<\/strong>, lupus discoid<\/strong>, \u0219i sindromul Sj\u00f6gren<\/strong>. Doz\u0103: 400 mg\/zi pentru boli autoimune (mentenan\u021b\u0103 pe termen lung \u2264 5 mg\/kg\/zi greutate corporal\u0103 real\u0103); 800 mg doz\u0103 de \u00eenc\u0103rcare urmat\u0103 de 400 mg la 6\/24\/48 h pentru malarie acut\u0103 necomplicat\u0103 sensibil\u0103 la clorochin\u0103. Screening oftalmologic obligatoriu la baz\u0103 + anual<\/strong> dup\u0103 5 ani de utilizare continu\u0103 pentru a detecta retinopatia. Zonele endemice moderne (Africa subsaharian\u0103, India, Asia de Sud-Est, Amazonia) au rezisten\u021b\u0103 larg r\u0103sp\u00e2ndit\u0103 la clorochin\u0103 \u2014 hidroxiclorochina NU este profilaxia corect\u0103 pentru aceste destina\u021bii. Lua\u021bi cu alimente pentru a reduce disconfortul gastrointestinal.<\/p>\n<\/div>\n

\ud83c\udfed Produc\u0103tor certificat WHO-GMP<\/strong>  \u00b7  \ud83d\udce6 Ambalaj discret<\/strong>  \u00b7  \ud83c\udf0d Livrare \u00een toat\u0103 lumea<\/strong>  \u00b7  \u2b50 Peste 1.400 de recenzii ale clien\u021bilor<\/a><\/strong><\/div>\n

\ud83d\udee1\ufe0f Fiecare comand\u0103 este acoperit\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

HCQS este procurat de la un produc\u0103tor certificat WHO-GMP \u0219i expediat \u00een \u00eentreaga lume \u00een ambalaje discrete. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a> \u0219i sprijinit\u0103 de Peste 1.400 de recenzii ale clien\u021bilor<\/a>. Livrare worldwide f\u0103r\u0103 documenta\u021bie medical\u0103.<\/p>\n

Despre HCQS<\/h2>\n

HCQS este un comprimat de sulfat de hidroxiclorochin\u0103 cu multiple doze, fabricat de Cipla \u00een condi\u021bii certificate WHO-GMP. Hidroxiclorochina este un antimalaric din clasa 4-aminochinolinei care serve\u0219te \u0219i ca medicament antireumatic modificator de boal\u0103 sintetic conven\u021bional (csDMARD)<\/strong> pentru artrita reumatoid\u0103 u\u0219oar\u0103 p\u00e2n\u0103 la moderat\u0103 \u0219i boli ale \u021besutului conjunctiv, av\u00e2nd cel mai sc\u0103zut profil de toxicitate dintre toate DMARD-urile atunci c\u00e2nd este dozat corect.<\/p>\n

Cum func\u021bioneaz\u0103 hidroxiclorochina<\/h2>\n

Hidroxiclorochina se acumuleaz\u0103 \u00een lizozomii acizi ai celulelor. \u00cen parazi\u021bii malariei<\/strong> interfer\u0103 cu digestia hemoglobinei \u00een vacuola alimentar\u0103, permi\u021b\u00e2nd acumularea de hem toxic care ucide parazitul. \u00cen boli autoimune<\/strong> efectul lizozomotropic cre\u0219te pH-ul lizozomal, care interfereaz\u0103 cu procesarea antigenelor de c\u0103tre celulele dendritice, atenueaz\u0103 semnalizarea receptorilor Toll-like (\u00een special TLR-7 \u0219i TLR-9 care recunosc acizi nucleici proprii) \u0219i reduce produc\u021bia de interferon-\u03b1. Mecanismul dublu explic\u0103 de ce un singur medicament trateaz\u0103 dou\u0103 boli neasem\u0103n\u0103toare.<\/p>\n

Timpul de \u00eenjum\u0103t\u0103\u021bire este de ~40 de zile (stare stabil\u0103 4\u20136 s\u0103pt\u0103m\u00e2ni). Efectul asupra bolii autoimune dureaz\u0103 8\u201312 s\u0103pt\u0103m\u00e2ni pentru a se dezvolta \u0219i continu\u0103 s\u0103 se ad\u00e2nceasc\u0103 pe parcursul a 6 luni \u2014 r\u0103bdarea \u0219i aderen\u021ba sunt importante.<\/p>\n

Indica\u021bii \u0219i dozaj<\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n
Indica\u021bie<\/th>\nDoza<\/th>\nDurat\u0103 \/ observa\u021bii<\/th>\n<\/tr>\n<\/thead>\n
Artrit\u0103 reumatoid\u0103 (u\u0219oar\u0103\u2013moderat\u0103)<\/td>\n200\u2013400 mg\/zi \u00een 1\u20132 doze divizate (maxim 5 mg\/kg\/zi greutate corporal\u0103 real\u0103)<\/td>\nEfect \u00een 8\u201312 s\u0103pt\u0103m\u00e2ni. Men\u021binere pe termen lung. Adesea combinat cu metotrexat sau sulfasalazin\u0103.<\/td>\n<\/tr>\n
Lupus eritematos sistemic (LES)<\/td>\n200\u2013400 mg\/zi, max 5 mg\/kg\/zi<\/td>\nTerapie de baz\u0103 pentru aproape to\u021bi pacien\u021bii cu SLE conform EULAR \u2014 reduce recidivele, afectarea organelor, tromboza \u0219i \u00eembun\u0103t\u0103\u021be\u0219te supravie\u021buirea.<\/td>\n<\/tr>\n
Lupus discoid\/cutanat<\/td>\n200\u2013400 mg\/zi<\/td>\nTratament sistemic de prim\u0103 inten\u021bie pentru lupus cutanat pur. Poate dura 8\u201312 s\u0103pt\u0103m\u00e2ni pentru \u00eembun\u0103t\u0103\u021biri vizibile.<\/td>\n<\/tr>\n
sindromul Sj\u00f6gren<\/td>\n200\u2013400 mg\/zi<\/td>\n\u00cembun\u0103t\u0103\u021bire moderat\u0103 a oboselii \u0219i artralgiei; efect redus asupra usc\u0103ciunii.<\/td>\n<\/tr>\n
Malarie acut\u0103 necomplicat\u0103 cu P. falciparum\/P. vivax\/P. ovale\/P. malariae sensibil\u0103 la clorochin\u0103<\/td>\n800 mg doz\u0103 de \u00eenc\u0103rcare \u2192 400 mg la 6 h \u2192 400 mg la 24 h \u2192 400 mg la 48 h (total 2 g \u00een 48 h)<\/td>\nDoar pentru tratament \u2014 \u00een zone sensibile la clorochin\u0103. Ad\u0103uga\u021bi primaquin\u0103 pentru vindecarea radical\u0103 a vivax\/ovale.<\/td>\n<\/tr>\n
Profilaxie pentru malarie sensibil\u0103 la clorochin\u0103<\/td>\n400 mg o dat\u0103 pe s\u0103pt\u0103m\u00e2n\u0103<\/td>\n\u00cencepe\u021bi cu 1\u20132 s\u0103pt\u0103m\u00e2ni \u00eenainte de c\u0103l\u0103torie, continua\u021bi s\u0103pt\u0103m\u00e2nal \u00een timpul expunerii, continua\u021bi 4 s\u0103pt\u0103m\u00e2ni dup\u0103 \u00eentoarcere. Utilitate limitat\u0103 \u2014 majoritatea destina\u021biilor sunt rezistente.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
Avertisment toxicitate retinal\u0103.<\/strong> Hidroxiclorochina se acumuleaz\u0103 \u00een epiteliul pigmentar retinal. Risc de maculopatie \u00een \u201eochi de taur\u201d ireversibil\u0103<\/strong> cre\u0219te semnificativ dup\u0103 5 ani de utilizare continu\u0103, \u00een special la doze > 5 mg\/kg\/zi greutate corporal\u0103 real\u0103, cu insuficien\u021b\u0103 renal\u0103, cu tamoxifen concomitent sau la pacien\u021bii cu boli retiniene preexistente. Recomand\u0103rile Academiei Americane de Oftalmologie \/ Colegiului Regal de Oftalmologi: examen de fund de ochi la \u00eenceputul terapiei pe termen lung + screening anual \u00eencep\u00e2nd cu anul 5.<\/strong> folosind OCT spectral-domain, c\u00e2mp vizual automat 10-2 (obiect de test alb) \u0219i autofluorescen\u021b\u0103 de fund. Screening mai devreme dac\u0103 doza > 5 mg\/kg\/zi, CrCl renal < 60 mL\/min sau tamoxifen concomitent. \u00centrerupe\u021bi medicamentul la primele semne de pre-toxicitate \u2014 leziunile deja stabilite nu se inverseaz\u0103.<\/div>\n
Not\u0103 G6PD.<\/strong> Hidroxiclorochina are un semnal de hemoliz\u0103 G6PD mult mai mic dec\u00e2t primaquina, dar exist\u0103 rapoarte de cazuri \u00een deficien\u021b\u0103 sever\u0103 de G6PD. Dac\u0103 statutul G6PD este necunoscut, monitoriza\u021bi hemoliza (urin\u0103 \u00eenchis\u0103, paloare, oboseal\u0103) \u00een primele s\u0103pt\u0103m\u00e2ni ale terapiei cu doze mari.<\/div>\n

Program de monitorizare<\/h2>\n
\n\n\n\n\n\n\n\n\n\n
Punct de timp<\/th>\nInvestiga\u021bie<\/th>\nMotiv<\/th>\n<\/tr>\n<\/thead>\n
De baz\u0103<\/td>\nExamen ocular (fund de ochi + OCT + c\u00e2mp vizual), FBC, U&E, LFTs, glucoz\u0103, greutate<\/td>\nStabilirea liniei de baz\u0103 a retinei + calculul dozei \u00een func\u021bie de greutatea real\u0103 + screening contraindicatii.<\/td>\n<\/tr>\n
Lunile 1\u20136<\/td>\nEvaluarea simptomelor la fiecare contact clinic.<\/td>\nToleran\u021b\u0103 gastrointestinal\u0103, cefalee, tulbur\u0103ri de stare, erup\u021bii cutanate, sl\u0103biciune muscular\u0103.<\/td>\n<\/tr>\n
Anul 1, apoi anual<\/td>\nHemogram\u0103 complet\u0103 + teste de func\u021bie hepatic\u0103<\/td>\nCitopenii rare \u0219i hepatotoxicitate rar\u0103.<\/td>\n<\/tr>\n
Anul 5, apoi anual<\/td>\nEvaluare oftalmologic\u0103 complet\u0103 (OCT + c\u00e2mp vizual 10-2 + autofluorescen\u021b\u0103 de fundus)<\/td>\nDetectarea precoce a retinopatiei \u00eenainte de apari\u021bia leziunilor ireversibile.<\/td>\n<\/tr>\n
Bazat pe simptome<\/td>\nCK + EMG \u00een caz de sl\u0103biciune proximal\u0103; conduc\u021bie nervoas\u0103 \u00een caz de simptome neuropatice<\/td>\nMiopatie rar\u0103 \/ neuromiopatie la utilizare pe termen lung.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Efecte secundare<\/h2>\n